SNCA

SNCA rs356219 — The Alpha-Synuclein Expression Variant Driving Earlier Parkinson's Onset

The SNCA gene | Alpha-synuclein (SNCA) was the first gene linked to Parkinson's disease; it encodes the protein that forms the pathological hallmark of PD — Lewy bodies contains multiple independent risk variants. rs356219 sits approximately 9 kilobases downstream of SNCA in a regulatory region that controls how much alpha-synuclein protein the cell produces. Unlike rs356182 — which acts through neuronal differentiation pathways — rs356219 works primarily by upregulating SNCA gene expression: carriers of the G allele have measurably higher alpha-synuclein levels in blood and specific brain regions. This is the variant's defining characteristic, and it makes rs356219 one of the most actionable SNCA risk markers because elevated alpha-synuclein is directly tied to aggregation, Lewy body formation, and dopaminergic neuron death.

The G allele has been consistently identified as a risk factor across twelve or more independent case-control studies spanning European, East Asian, and South American populations, making it one of the most robustly replicated common SNCA risk variants.

The Mechanism

rs356219 functions as a regulatory variant | A variant that alters gene expression rather than protein sequence; these often reside in promoters, enhancers, or 3′UTR regions in the 3′ region of the SNCA locus. The G allele alters the activity of this regulatory element in a direction that boosts SNCA transcription. Studies in CD45+ blood cells | Circulating immune cells express SNCA and can serve as a peripheral proxy for central nervous system expression confirmed that individuals carrying the G allele have significantly elevated SNCA mRNA levels and higher alpha-synuclein protein concentrations compared to AA homozygotes. Similarly, plasma alpha-synuclein is elevated in G-allele carriers in a dose-dependent additive manner, suggesting each additional G allele incrementally raises the ambient level of this aggregation-prone protein.

The downstream consequence is straightforward: more alpha-synuclein means a higher probability of misfolding, oligomer formation, and ultimately aggregation into the insoluble fibrils that kill dopaminergic neurons in the substantia nigra. This dose-response model explains why GG homozygotes show earlier onset and more rapid cognitive decline than AG heterozygotes, who in turn show higher risk than AA individuals.

The Evidence

The seminal genetic association study | Mata et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Archives of Neurology, 2010 enrolled 1,956 PD patients and 2,112 controls and identified rs356219 as the most significant SNCA marker (OR 1.41, 95% CI 1.28–1.55; p=1.6×10⁻¹²). Crucially, the study also measured plasma alpha-synuclein in a subset, demonstrating that the risk allele correlates with higher protein levels — establishing a plausible dose-response mechanism.

A Chinese Han population study | Pan et al. SNP rs356219 of the alpha-synuclein gene is associated with Parkinson's disease in a Chinese Han population. Parkinsonism & Related Disorders, 2012 (403 patients, 315 controls) found OR 1.88 (95% CI 1.27–2.78) for variant genotypes, with GG homozygotes comprising 42.2% of PD patients versus 32.4% of controls. A follow-up Chinese study of 685 patients | Li et al. SNCA rs356219 variant increases risk of sporadic Parkinson's disease in ethnic Chinese. Am J Med Genet B, 2013 confirmed these findings with OR 1.81 (95% CI 1.54–2.13; p=5.71×10⁻¹³) and documented earlier age at disease onset in G-allele carriers.

A 2025 systematic review and meta-analysis | Common SNCA genetic variants and Parkinson's disease risk. International Journal of Molecular Sciences, 2025 across 27 studies found rs356219 demonstrated the strongest risk association of any common SNCA variant, particularly under the recessive model (OR 1.69, 95% CI 1.49–1.92). Under the allelic model the overall OR was 1.35 (95% CI 1.22–1.50).

A 2021 systematic review | Pedersen et al. A systematic review of associations between common SNCA variants and clinical heterogeneity in PD. npj Parkinson's Disease, 2021 covering 58 studies confirmed that the most reproducible clinical association for any common SNCA variant is rs356219 and earlier age at onset of PD. A Brazilian cohort study | Campelo et al. Variants in SNCA gene are associated with PD risk and cognitive symptoms. Front Aging Neurosci, 2017 found that GG homozygotes with PD showed OR 5.74 (95% CI 1.42–23.21) for cognitive impairment, and a Scandinavian longitudinal study confirmed that GG genotype associates with faster annual cognitive decline as measured by MMSE.

A gene-environment study | Lucchini et al. Metal exposure and SNCA rs356219 polymorphism associated with Parkinson disease. Front Neurol, 2020 of 432 cases and 444 controls in an industrially exposed Italian region found that the homozygous risk genotype alone confers OR 2.03 for PD, and that metal exposure independently adds further risk — with a directional (though not statistically significant) interaction suggesting carriers face compounded hazard when exposed to manganese and other neurotoxic metals.

Practical Actions

The central mechanism — elevated alpha-synuclein due to higher SNCA expression — shapes the specific interventions that make sense for G-allele carriers. The goal is not to lower risk of developing any disease, but to slow the aggregation of the excess protein that this variant produces.

Coenzyme Q10 targets several mechanisms directly relevant to alpha-synuclein toxicity: mitochondrial complex I dysfunction (the primary energy failure in PD), oxidative stress that promotes alpha-synuclein misfolding, and neuroinflammation. The ubiquinol form is preferred for absorption. Coffee and caffeine have shown consistent neuroprotective associations in PD, including evidence that caffeine reduces the toxicity of alpha-synuclein oligomers and restores autophagy — the cellular process that clears misfolded protein aggregates.

Reducing exposure to neurotoxic metals is particularly relevant for this variant: manganese specifically promotes alpha-synuclein overexpression and aggregation, and the gene-environment interaction data for rs356219 support avoiding occupational or environmental manganese/heavy metal exposure. Pesticides containing manganese compounds (maneb, mancozeb) are a specific concern for agricultural workers.

For those who develop PD, knowing the rs356219 genotype may inform prognosis: GG homozygotes face higher risk of cognitive decline and should discuss early cognitive monitoring with their neurologist.

Interactions

rs356219 is distinct from and independent of rs356182 (another SNCA risk variant already profiled in this database). These two variants reside in different linkage disequilibrium blocks and likely confer risk through different mechanisms — rs356182 acting through neuronal differentiation, rs356219 through SNCA expression levels. Carriers of risk alleles at both loci may face incrementally higher cumulative PD susceptibility.

The most clinically significant interaction is with LRRK2 G2019S, the most common dominant PD mutation. In LRRK2 G2019S carriers, the rs356219 G allele shifts age of onset approximately 4 years earlier (AG+GG carriers: mean onset ~58 years vs AA carriers: ~62 years; p=0.006). Individuals who carry both LRRK2 G2019S and rs356219 G risk alleles represent a high-priority group for early monitoring and preventive intervention.

rs356165, another 3′-region SNCA variant, co-occurs with rs356219 in some studies and may contribute additional independent risk, though its LD relationship with rs356219 varies by ancestry.